Identifying novel brain active molecules: Developing an integrated bioengineering & in silico screening platform technology (IBIS)

识别新型大脑活性分子：开发集成生物工程

• 批准号: 131001
• 金额: $ 19.06万
• 依托单位: PHARMIDEX PHARMACEUTICAL SERVICES LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131001
• 关键词: Identifying; novel; brain; active; molecules

The major imperative of the pharmaceutical industry is to effectively translate insights gained from basic research into new medicines. This task is toughest for brain disorders such as Parkinson’s and Alzheimer’s disease. The WHO has indicated that this will become the major medical need of the 21st century. Brain drugs take longer to get to market and their attrition rate is greater, because of the presence of the blood-brain-barrier (BBB), which severely restricts the movement of medicines into the brain. In this industry led project we intend to explore the feasibility of a platform technology to screen for production of novel natural bioactive molecules by microbial biotransformation that are capable of crossing the BBB. The project success provides a unique business opportunity for SME partners for revenue growth, extra chemical library resources to pharmaceutical R&D and the potential to develop new therapies for the treatment of neurological diseases for patients.

制药行业的当务之急是有效地将从基础研究中获得的见解转化为新药。对于帕金森氏症和阿尔茨海默氏症等脑部疾病来说，这项任务是最艰巨的。世界卫生组织表示，这将成为21世纪世纪的主要医疗需求。由于血脑屏障（BBB）的存在，脑药物需要更长的时间才能进入市场，其损耗率更高，这严重限制了药物进入大脑的运动。在这个行业主导的项目中，我们打算探索平台技术的可行性，以筛选通过微生物生物转化产生能够穿过BBB的新型天然生物活性分子。该项目的成功为中小企业合作伙伴提供了一个独特的商业机会，可促进收入增长，为制药研发提供额外的化学库资源，并有可能为患者开发治疗神经系统疾病的新疗法。